University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Dieldrin (CAS 60-57-1)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
no positive no positive liv liv no positive 0.912m,P

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
Male Female
no positive no positive no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. P = 100% of dosed animals had tumors at a target site in an experiment in this species.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Dieldrin: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.

Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

DIELDRIN 60-57-1 2092 H f syg eat 23m26 1000 0 2.09mg 6.27mg 18.8mg Cabral;clet,6,241-246;1979 liv hpt e * P<.3 - 28.7mg n.s.s. 0/6 0/2 0/8 1/9 lun tum e no dre P=1. - 11.8mg n.s.s. 0/39 0/32 0/34 0/38 tba mix e * P<.6 - 54.3mg n.s.s. 5/39 1/32 5/34 5/38 2093 H m syg eat 26m26 1000 0 1.84mg 5.52mg 16.6mg liv hpt e * P<.4 - 32.2mg n.s.s. 0/2 0/3 0/5 1/13 lun ade e * P<.2 - n.s.s. 0/40 0/32 0/32 1/40 tba mix e 69.9mg * P<.05 - 26.5mg n.s.s. 3/40 5/32 5/32 10/40 2094 M f b6c eat 80w91 TR21 : 0 .290mg .560mg TBA MXB s no dre P=1. - .878mg n.s.s. 3/20 13/50 9/50 liv MXB s 1.09mg \ P<.06 .446mg n.s.s. 0/20 6/50 (2/50) liv:hpa,hpc,nnd. lun MXB s 5.05mg * P<.4 1.75mg n.s.s. 0/20 2/50 2/50 lun:a/a,a/c. 2095 M m b6c eat 80w91 TR21 : 0 .260mg .520mg TBA MXB s 1.06mg * P<.2 - .399mg n.s.s. 4/20 14/50 18/50 liv MXB s 1.04mg * P<.2 .422mg n.s.s. 3/20 12/50 16/50 liv:hpa,hpc,nnd. lun MXB s 24.7mg * P<.9 1.30mg n.s.s. 1/20 4/50 3/50 lun:a/a,a/c. 2096 M m b6c eat 80w89 TR21 : pool 0 .260mg .520mg liv hpc s 1.35mg * P<.08 a .508mg n.s.s. 17/95 12/50 16/50 2097 M b c3e eat 24m24 20a 0 1.25mg Davis;txap,4,187-189;1962 liv hpa e 4.09mg P<.0005 + 2.40mg 10.6mg 9/134 36/148 lun ade e no dre P=1. 27.8mg n.s.s. 3/134 1/148 lun car e no dre P=1. 38.1mg n.s.s. 0/134 0/148 2098 M b c3e eat 24m24 22a 0 1.25mg Epstein(review) {H J Davis};stev,4,1-52;1975 liv hpt 3.08mg P<.0005 1.95mg 6.43mg 27/200 69/200 liv hpc P<.8 16.8mg n.s.s. 4/200 5/200 tba ben 3.10mg P<.0005 1.94mg 6.79mg 30/200 71/200 tba mal no dre P=1. 24.7mg n.s.s. 21/200 9/200 2099 M f cf1 eat 26m26 89 0 1.30mg Thorpe;fctx,11,433-442;1973 liv mix e .567mg P<.0005 + .298mg 1.27mg 10/44 26/30 liv lct e 1.59mg P<.0005 + .842mg 3.48mg 0/44 14/30 lun tum e no dre P=1. - 4.36mg n.s.s. 27/44 8/30 2100 M f cf1 eat 28m32 103a 0 12.8ug .124mg 1.30mg Walker;fctx,11,415-432;1973 lun ade ae .606mg Z P<.002 - .300mg 2.84mg 48/297 23/90 30/87 (15/148) liv mix ae .642mg * P<.0005 + .481mg .870mg 39/297 24/90 32/87 136/148 liv lpb ae 1.96mg Z P<.0005 1.49mg 2.66mg 0/297 4/90 5/87 81/148 lun car ae 1.78mg Z P<.06 - .624mg n.s.s. 18/297 12/90 12/87 (0/148) 2101 M f cf1 eat 25m30 103b 0 .162mg .325mg .650mg 1.30mg 2.60mg liv mix aes 1.49mg * P<.0005 + .959mg 2.69mg 8/78 5/30 12/28 18/30 9/17 16/21 liv lpb aes 9.72mg * P<.0005 4.87mg 29.5mg 0/78 0/30 1/28 5/30 2/17 3/21 lun ade aes no dre P=1. - 2.03mg n.s.s. 24/78 7/30 3/28 (3/30 1/17 0/21) lun car aes no dre P=1. - 30.6mg n.s.s. 8/78 0/30 0/28 1/30 0/17 0/21 2102 M f cf1 eat 90w90 103c 0 1.30mg liv lpb e 2.59mg P<.007 .978mg 31.8mg 0/22 5/22 liv mix e 1.05mg P<.02 + .438mg n.s.s. 5/22 13/22 lun ade e no dre P=1. - 2.93mg n.s.s. 7/22 2/22 lun car e no dre P=1. - 4.41mg n.s.s. 0/22 0/22 2103 M f cf1 eat 30m30 103d 0 1.30mg liv mix e 3.11mg P<.02 + 1.20mg n.s.s. 3/28 8/19 liv lpb e 12.1mg P<.06 2.98mg n.s.s. 0/28 2/19 lun ade e no dre P=1. - 7.71mg n.s.s. 5/28 0/19 lun car e no dre P=1. - 7.71mg n.s.s. 0/28 0/19 2104 M f cf1 eat 25m25 103e 0 1.30mg liv mix e 1.16mg P<.002 + .548mg 5.32mg 4/24 15/24 liv lpb e 3.96mg P<.007 1.50mg 51.4mg 0/24 5/24 lun ade e 5.69mg P<.4 - 1.41mg n.s.s. 4/24 7/24 lun car e no dre P=1. - 6.68mg n.s.s. 3/24 0/24 2105 M m cf1 eat 26m26 89 0 1.20mg Thorpe;fctx,11,433-442;1973 liv mix e noTD50 P<.0005 + n.s.s. .469mg 11/45 30/30 liv lct e 1.28mg P<.0005 + .682mg 3.03mg 2/45 16/30 lun tum e no dre P=1. - 2.87mg n.s.s. 27/45 11/30 2106 M m cf1 eat 28m31 103a 0 11.8ug .118mg 1.15mg Walker;fctx,11,415-432;1973 liv mix ae .547mg * P<.0005 + .416mg .729mg 58/288 32/124 34/111 165/176 liv lpb ae 1.68mg * P<.0005 1.29mg 2.25mg 12/288 5/124 9/111 100/176 lun ade ae 2.13mg Z P<.5 - .439mg n.s.s. 95/288 47/124 42/111 (32/176) lun car ae 3.71mg Z P<.4 - .844mg n.s.s. 23/288 14/124 13/111 (2/176) 2107 M m cf1 eat 26m30 103b 0 .150mg .300mg .600mg 1.20mg 2.40mg liv mix aes 1.12mg Z P<.0005 + .714mg 2.09mg 9/78 6/30 13/30 26/30 5/11 12/17 liv lpb aes 4.66mg * P<.0005 2.59mg 9.94mg 0/78 2/30 1/30 3/30 1/11 9/17 lun ade aes no dre P=1. - 3.96mg n.s.s. 45/78 17/30 11/30 14/30 2/11 (1/17) lun car aes no dre P=1. - 14.7mg n.s.s. 1/78 1/30 1/30 1/30 0/11 0/17 2108 M m cf1 eat 30m30 103c 0 1.20mg liv mix e .913mg P<.002 + .420mg 3.87mg 8/23 20/24 liv lpb e 5.12mg P<.04 1.85mg n.s.s. 1/23 6/24 lun ade e no dre P=1. - 4.13mg n.s.s. 7/23 4/24 lun car e no dre P=1. - 8.99mg n.s.s. 0/23 0/24 2109 M m cf1 eat 30m30 103d 0 1.20mg liv mix e 1.91mg P<.04 + .589mg n.s.s. 7/30 6/10 liv lpb e 6.58mg P<.2 1.41mg n.s.s. 1/30 2/10 lun ade e no dre P=1. - 2.93mg n.s.s. 13/30 1/10 lun car e no dre P=1. - 3.75mg n.s.s. 1/30 0/10 2110 M m cf1 eat 26m29 103e 0 1.06mg liv mix e .713mg P<.002 + .305mg 3.96mg 10/24 19/22 liv lpb e 4.02mg P<.006 1.52mg 35.7mg 0/24 5/22 lun ade e no dre P=1. - 1.93mg n.s.s. 11/24 8/22 lun car e no dre P=1. - 6.86mg n.s.s. 1/24 0/22 2111 R b osm eat 24m24 23 0 22.5ug 90.0ug .450mg 2.25mg 4.50mg 6.75mg Fitzhugh;fctx,2,551-562; 1964 lun lys es no dre P=1. 35.4mg n.s.s. 1/17 4/22 2/23 2/18 1/20 0/18 0/11 tba mix es no dre P=1. + 23.3mg n.s.s. 3/17 8/22 8/23 4/18 4/20 3/18 0/11 2112 R f osm eat 21m26 TR21 : 0 1.10mg 1.70mg TBA MXB sv no dre P=1. - .635mg n.s.s. 7/10 39/50 (27/50) liv MXB sv 38.4mg * P<.8 9.44mg n.s.s. 0/10 1/50 1/50 liv:hpa,hpc,nnd. 2113 R f osm eat 21m25 TR21 : pool 0 1.10mg 1.70mg adr MXA sv# 4.42mg \ P<.003 - 1.80mg 22.2mg 0/60 6/50 (2/50) adr:coa,coc. S 2114 R f f34 eat 24m24 TR22 : 0 .100mg .500mg 2.50mg TBA MXB a * P<1. - 1.62mg n.s.s. 17/24 17/24 16/24 14/24 liv MXB a no dre P=1. n.s.s. n.s.s. 0/24 0/24 0/24 0/24 liv:hpa,hpc,nnd. 2115 R f osm eat 28m29 1004 0 .960mg 1.44mg 2.40mg Deichmann;imed,39,426-434;1970 liv tum ev no dre P=1. - 6.19mg n.s.s. 0/88 0/48 0/41 0/41 tba mix ev no dre P=1. - 15.1mg n.s.s. 60/88 23/48 16/41 16/41 2116 R m osm eat 21m26 TR21 : 0 .880mg 1.36mg TBA MXB sv 3.34mg * P<.6 - .774mg n.s.s. 5/10 24/50 22/50 liv MXB sv no dre P=1. 7.38mg n.s.s. 1/10 0/50 1/50 liv:hpa,hpc,nnd. 2117 R m f34 eat 24m24 TR22 : 0 80.0ug .400mg 2.00mg TBA MXB a 7.28mg * P<.4 - 1.64mg n.s.s. 5/24 9/24 7/24 9/24 liv MXB a no dre P=1. n.s.s. n.s.s. 0/24 0/24 0/24 0/24 liv:hpa,hpc,nnd. 2118 R m osm eat 29m29 1004 0 .768mg 1.15mg 1.92mg Deichmann;imed,39,426-434;1970 liv hem ev no dre P=1. - 4.90mg n.s.s. 1/75 0/48 0/38 0/44 tba mix ev no dre P=1. - 8.93mg n.s.s. 19/75 4/48 7/38 (1/44) 2119 R f cfe eat 24m24 100 0 5.00ug 50.0ug .500mg Stevenson;txap,36,247-254;1976 tba mix e no dre P=1. - .388mg n.s.s. 18/43 18/23 16/23 13/23 2120 R m cfe eat 24m24 100 0 4.00ug 40.0ug .400mg tba mix e 2.01mg * P<.5 - .384mg n.s.s. 12/43 9/23 5/23 9/23 2121 R f nss eat 24m24 1002 0 .125mg .625mg 1.25mg Cleveland;aenh,13,195-198;1966 tba tum 57.2mg * P<.9 - 3.29mg n.s.s. 6/60 7/40 7/40 5/40 2122 R m nss eat 24m24 1002 0 .100mg .500mg 1.00mg tba tum 40.5mg * P<.8 - 4.09mg n.s.s. 3/60 1/40 3/40 2/40

Mutagenicity in Salmonella: negative
SMILES Code for Dieldrin: Cl\C2=C(/Cl)C3(Cl)C1C4CC(C1C2(Cl)C3(Cl)Cl)C5OC45
InChI Code for Dieldrin: InChI=1/C12H8Cl6O/c13-8-9(14)11(16)5-3-1-2(6-7(3)19-6)4(5)10(8,15)12(11,17)18/h2-7H,1H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Dieldrin: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader
Excel documents are best viewed with the free Excel® Viewer